In:
Annals of Neurology, Wiley, Vol. 59, No. 2 ( 2006-02), p. 404-407
Abstract:
Our objective was to investigate a role of the intracellular tyrosine phosphatase PTPN22*R620W variant in autoimmune myasthenia gravis (MG), considering disease heterogeneity. Methods We used a case–control design, comparing 470 patients and 296 controls, all French whites. Patients were categorized depending on the presence of a thymoma and serum anti‐titin antibodies. Results The 620W risk allele was increased in 293 nonthymoma patients without anti‐titin antibodies (odds ratio, 1.97; 95% confidence interval, 1.32–2.97, p = 0.00059) but not in nonthymoma patients with anti‐titin antibodies or in thymoma patients. Interpretation Our genetic findings strengthen the concept that these groups of patients correspond to etiologically distinct disease entities. Ann Neurol 2006;59:404–407
Type of Medium:
Online Resource
ISSN:
0364-5134
,
1531-8249
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
2037912-2
Permalink